214 related articles for article (PubMed ID: 20304499)
1. Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.
Avni I; Garzozi HJ; Barequet IS; Segev F; Varssano D; Sartani G; Chetrit N; Bakshi E; Zadok D; Tomkins O; Litvin G; Jacobson KA; Fishman S; Harpaz Z; Farbstein M; Yehuda SB; Silverman MH; Kerns WD; Bristol DR; Cohn I; Fishman P
Ophthalmology; 2010 Jul; 117(7):1287-93. PubMed ID: 20304499
[TBL] [Abstract][Full Text] [Related]
2. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
[TBL] [Abstract][Full Text] [Related]
3. CF101 for dry eye.
Ashar JN; Mathur A; Sangwan V
Ophthalmology; 2011 May; 118(5):1011-2; author reply 1012. PubMed ID: 21539995
[No Abstract] [Full Text] [Related]
4. Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial.
David M; Gospodinov DK; Gheorghe N; Mateev GS; Rusinova MV; Hristakieva E; Solovastru LG; Patel RV; Giurcaneanu C; Hitova MC; Purcaru AI; Horia B; Tsingov II; Yankova RK; Kadurina MI; Ramon M; Rotaru M; Simionescu O; Benea V; Demerdjieva ZV; Cosgarea MR; Morariu HS; Michael Z; Cristodor P; Nica C; Silverman MH; Bristol DR; Harpaz Z; Farbstein M; Cohen S; Fishman P
J Drugs Dermatol; 2016 Aug; 15(8):931-8. PubMed ID: 27537992
[TBL] [Abstract][Full Text] [Related]
5. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
[TBL] [Abstract][Full Text] [Related]
6. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.
Stevenson D; Tauber J; Reis BL
Ophthalmology; 2000 May; 107(5):967-74. PubMed ID: 10811092
[TBL] [Abstract][Full Text] [Related]
8. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.
Matsumoto Y; Ohashi Y; Watanabe H; Tsubota K;
Ophthalmology; 2012 Oct; 119(10):1954-60. PubMed ID: 22739038
[TBL] [Abstract][Full Text] [Related]
10. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.
Tauber J; Davitt WF; Bokosky JE; Nichols KK; Yerxa BR; Schaberg AE; LaVange LM; Mills-Wilson MC; Kellerman DJ
Cornea; 2004 Nov; 23(8):784-92. PubMed ID: 15502479
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
[TBL] [Abstract][Full Text] [Related]
12. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye.
Kinoshita S; Oshiden K; Awamura S; Suzuki H; Nakamichi N; Yokoi N;
Ophthalmology; 2013 Jun; 120(6):1158-65. PubMed ID: 23490326
[TBL] [Abstract][Full Text] [Related]
13. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
Sall K; Stevenson OD; Mundorf TK; Reis BL
Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
[TBL] [Abstract][Full Text] [Related]
14. Targeting the A3 adenosine receptor for glaucoma treatment (review).
Fishman P; Cohen S; Bar-Yehuda S
Mol Med Rep; 2013 Jun; 7(6):1723-5. PubMed ID: 23563604
[TBL] [Abstract][Full Text] [Related]
15. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
[TBL] [Abstract][Full Text] [Related]
16. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
[TBL] [Abstract][Full Text] [Related]
17. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.
Sosne G; Dunn SP; Kim C
Cornea; 2015 May; 34(5):491-6. PubMed ID: 25826322
[TBL] [Abstract][Full Text] [Related]
18. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
[TBL] [Abstract][Full Text] [Related]
19. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study.
Tauber J; Berdy GJ; Wirta DL; Krösser S; Vittitow JL;
Ophthalmology; 2023 May; 130(5):516-524. PubMed ID: 36574848
[TBL] [Abstract][Full Text] [Related]
20. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial.
David M; Akerman L; Ziv M; Kadurina M; Gospodinov D; Pavlotsky F; Yankova R; Kouzeva V; Ramon M; Silverman MH; Fishman P
J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):361-7. PubMed ID: 21504485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
